Bristol-Myers Squibb Company (NYSE:BMY) shares traded 0.38% higher at $77.45 on Wall Street last session.
In accordance with the data, 22 analysts cover Bristol-Myers Squibb Company (NYSE:BMY). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $90.00 and a low of $60.00, we find $83.00. Given the previous closing price of $77.16, this indicates a potential upside of 7.57 percent. BMY stock price is now 5.96% away from the 50-day moving average and 5.78% away from the 200-day moving average. The market capitalization of the company currently stands at $164.05B.
It has been rated a hold by 11 analysts and a buy by 9. Brokers who have rated the stock have averaged $80.33 as their price target over the next twelve months.
With the price target of $78, Credit Suisse recently initiated with Neutral rating for Bristol-Myers Squibb Company (NYSE: BMY)., while ‘Berenberg’ rates the stock as ‘Hold’.
In other news, Powell Ann, EVP, Chief Human Resources sold 16,250 shares of the company’s stock on Nov 09. The stock was sold for $1,307,312 at an average price of $80.45. Upon completion of the transaction, the EVP, Chief Human Resources now directly owns 34,226 shares in the company, valued at $2.65 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 07, EVP, Research & Early Dev. VESSEY RUPERT sold 45,910 shares of the business’s stock. A total of $3,621,381 was realized by selling the stock at an average price of $78.88. This leaves the insider owning 57,079 shares of the company worth $4.42 million. Insiders disposed of 933,571 shares of company stock worth roughly $72.31 million over the past 1 year. A total of 0.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in BMY stock. A new stake in Bristol-Myers Squibb Company shares was purchased by AMALGAMATED FINANCIAL CORP. during the first quarter worth $44,771,000. ARROWSTREET CAPITAL, LIMITED PARTNERSHIP invested $21,252,000 in shares of BMY during the first quarter. In the first quarter, CZECH NATIONAL BANK acquired a new stake in Bristol-Myers Squibb Company valued at approximately $19,224,000. ENDURANT CAPITAL MANAGEMENT LP acquired a new stake in BMY for approximately $12,293,000. BAADER BANK AKTIENGESELLSCHAFT purchased a new stake in BMY valued at around $12,124,000 in the second quarter. In total, there are 3,188 active investors with 79.40% ownership of the company’s stock.
During the past 12 months, Bristol-Myers Squibb Company has had a low of $53.22 and a high of $81.17. As of last week, the company has a debt-to-equity ratio of 1.20, a current ratio of 1.40, and a quick ratio of 1.30. The fifty day moving average price for BMY is $73.24 and a two-hundred day moving average price translates $73.29 for the stock.
The latest earnings results from Bristol-Myers Squibb Company (NYSE: BMY) was released for Sep, 2022. According to the Drug Manufacturers – General Company, earnings per share came in at $1.99, beating analysts’ expectations of $1.83 by 0.16. This compares to $0.69 EPS in the same period last year. The net profit margin was 14.30% and return on equity was 20.10% for BMY. The company reported revenue of $11.22 billion for the quarter, compared to $11.62 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -3.49 percent. For the current quarter, analysts expect BMY to generate $11.19B in revenue.
Moreover, the firm recently paid out its quarterly dividend on 11/01/2022. Investors who held shares on 10/07/2022 were paid a $0.54 dividend. On an annualized basis, this represents a $2.16 dividend and a 2.79% percent yield. There was an ex-dividend date of 10/06/2022 for this dividend. In terms of dividend payout ratio, BMY is presently at 68.30%.
Bristol-Myers Squibb Company(BMY) Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company’s products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.